EU Health Priorities Jurate Svarcaite Secretary General PGEU
Members: Professional Bodies & Pharmacists Associations 2016: 33 Countries Austria Belgium Bulgaria Croatia Cyprus Czech Rep Denmark Estonia Finland France Germany Greece Hungary Ireland Italy Luxembourg Malta Netherlands Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom Bosnia Herzegovina FYR Macedonia Norway Serbia Switzerland Turkey Ukraine
1959 2016 400.000 Community Pharmacists 160.000 Pharmacies 46 million citizens visit a pharmacy every day
Mission of PGEU PGEU, as a a rigorous, proactive & constructive stakeholder: Ensures our shared vision of Community Pharmacy is reflected in EU policy and legislative developments Advocates for the contribution community pharmacists make to health systems and to public health through the provision of health services and the promotion of the rational and appropriate use of medicines Promotes and develops cooperation in Community Pharmacy among the European nations
How do we do this? Working collaboratively with members to establish positions that reflect the view of the profession as a whole in Europe Establishing & maintaining working relationships with other European & International stakeholders Dedicated Secretariat who are central to the organisation Keeping patient care as the central focus
EU Health Law EU: complementary competence in health Focus on Public Health (Art 168 TFEU): limited powers towards improving health and preventing disease Legal competencies: standard blood (organ) products, organs, tissues and medicines Respecting the MS responsibilities for organisation, delivery and financing of medical care
Free movement: People Services Goods Capital EU Single Market
PGEU is involved in a number of legal dossiers Professional Recognition Directive Falsified Medicines Directive Medical Devices Regulation Health Claims on Botanicals Veterinary medicines Trade Agreements VAT Waste Directive
Professional Qualifications Recognition Directive (I)
Professional Qualifications Recognition The scope of pharmacist activities: Directive (II) (a) preparation of the pharmaceutical form of medicinal products; (b) manufacture and testing of medicinal products; (c) testing of medicinal products in a laboratory for the testing of medicinal products; (d) storage, preservation and distribution of medicinal products at the wholesale stage; (e) supply, preparation, testing, storage, distribution and dispensing of safe and efficacious medicinal products of the required quality in pharmacies open to the public; (f) preparation, testing, storage and dispensing of safe and efficacious medicinal products of the required quality in hospitals; (g) provision of information and advice on medicinal products as such, including on their appropriate use; (h) reporting of adverse reactions of pharmaceutical products to the competent authorities; (i) personalised support for patients who administer their medication; (j) contribution to local or national public health campaigns;
Digital single market
PGEU
AMR a major European challenge Why is AMR a serious threat to society and economy? 25 000 patients die annually in the EU alone as a result of infections caused by resistant bacteria. 1.5 billion euros each year extra healthcare costs and productivity losses due to multidrug-resistant bacteria in the EU. The consumption of specific antibiotics used for treatment of multidrug-resistant bacterial infections has increased significantly between 2010-2014. Some good news - There has been a significant decrease in antibiotic consumption in the community in 5 countries (Denmark, Luxembourg, Slovenia, Spain and Sweden).
Source: http://ec.europa.eu/dgs/health_food-safety/amr/docs/eb445_amr_generalfactsheet_en.pdf
Eurobarometer 2016 Source: http://ec.europa.eu/dgs/health_food-safety/amr/docs/eb445_amr_generalfactsheet_en.pdf
EAAD
National campaigns
THANK YOU www.pgeu.eu